NEW YORK, June 23, 2021 /PRNewswire/ -- AIkido Pharma
Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today
announced that the Company has filed a provisional patent
application for the use of ketamine and peptides to treat
Alzheimer's disease. The Company previously secured and
announced the acquisition of patent rights for use of peptides as a
drug delivery system. This patent application seeks patent
protection for the use of ketamine and these peptides to treat
Alzheimer's disease.
We believe that one of the biggest breakthroughs in the study of
depression has been the observation that ketamine can reverse
symptoms of depression within hours to days when given by
intravenous infusion. Additionally, the study of this
psychedelic in other fields of use is growing in popularity.
Alzheimer's disease is a progressive neurodegenerative disorder
that is associated with the destruction of higher brain structures,
such as those involved in memory and cognition. The disease leads
to deficits in cognitive function and declines in memory, learning,
language, and in the ability to perform intentional and purposeful
movements. Alzheimer's disease is also accompanied by concomitant
behavioral, emotional, interpersonal, and social deterioration.
Clinical management and treatment of Alzheimer's remains largely
inadequate. There is still an unmet need for effective methods to
prevent and treat the disease. Targeted delivery of a drug,
prodrug, or therapeutic agent to cells that cause a disease or are
affected by a disease can improve treatment of the disease. There
is a need for targeted delivery of drugs, prodrugs, or other
therapeutic agents effective in treating Alzheimer's. This
patent application is the next step in combining homing peptides
with a well-known psychedelic drug to treat this disease.
About AIkido Pharma Inc.
AIkido Pharma Inc. was
initially formed in 1967 and is a biotechnology Company with a
diverse portfolio of small-molecule anti-cancer therapeutics.
The Company's platform consists of patented technology from leading
universities and researchers, and we are currently in the process
of developing an innovative therapeutic drug platform through
strong partnerships with world renowned educational institutions,
including The University of Texas at Austin and University of
Maryland at Baltimore. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer and prostate
cancer. We are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology. The Company is also
developing a broad-spectrum antiviral platform that may potentially
inhibit replication of multiple viruses including Influenza virus,
SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this
press release constitute "forward-looking statements" within the
meaning of the federal securities laws. Words such as "may,"
"might," "will," "should," "believe," "expect," "anticipate,"
"estimate," "continue," "predict," "forecast," "project," "plan,"
"intend" or similar expressions, or statements regarding intent,
belief, or current expectations, are forward-looking statements.
While the Company believes these forward-looking statements are
reasonable, undue reliance should not be placed on any such
forward-looking statements, which are based on information
available to us on the date of this release. These forward-looking
statements are based upon current estimates and assumptions and are
subject to various risks and uncertainties, including without
limitation those set forth in the Company's filings with the SEC,
not limited to Risk Factors relating to its business contained
therein. Thus, actual results could be materially different. The
Company expressly disclaims any obligation to update or alter
statements whether as a result of new information, future events or
otherwise, except as required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.:
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-files-patent-application-for-the-use-of-ketamine-to-treat-alzheimers-disease-301318422.html
SOURCE AIkido Pharma Inc.